London open: FTSE swoops lower, dragged by Croda Intl
31st Oct 2013 08:45
- FTSE led lower by Croda Intl - Guidance sought from abroad - German consumer confidence falls techMARK 2,646.30 -0.70% FTSE 100 6,753.63 -0.36% FTSE 250 15,493.32 -0.58% The FTSE offered up few treats on Thursday, swooping 24 points lower in early trade, following the Federal Open Market Committ
Read moreAstrazeneca appoints new CFO as third quarter revenues fall - UPDATE
31st Oct 2013 07:26
- New CFO appointed - Revenues and profits fall in Q3 - Court trial over Pulmicort Respules patent continues AstraZeneca announced the appointment of Marc Dunoyer as Chief Financial Officer as it reported a fall in third quarter revenue. Dunoyer, currently Executive Vice President, Global Portfol
Read moreAstrazeneca begins third phase of asthma study
30th Oct 2013 07:54
- Phase III of Windward begins - Developing treatment for uncontrolled asthma Drugs giant AstraZeneca has started the third phase of the Windward programme for benralizumab, a potential treatment for severe uncontrolled asthma developed by MedImmune, the company's global biologics research and dev
Read moreLondon close: FTSE ends higher after UK data
28th Oct 2013 16:30
- FTSE closes modestly higher - Investors pause ahead of tomorrow's Fed meeting - Aggreko leads risers, Tullow is biggest faller techMARK 2,640.77 +0.06% FTSE 100 6,725.82 +0.07% FTSE 250 15,428.79 -0.41% The FTSE ultimately ended the session higher, albeit marginally, tracking some modest gains o
Read moreFTSE 100 movers: Aggreko tops leaders on full-year expectations
28th Oct 2013 14:44
Temporary power group Aggreko climbed into the top spot after it said it expected full year profits to be in line with market expectations despite the absence of a one-off lift from the London Olympics. Also on the rise was Randgold Resources after boss Mark Bristow said the miner is exploring furt
Read moreMonday broker round-up UPDATE
28th Oct 2013 08:55
Admiral Group: Numis raises target price from 1170p to 1425p upgrading to add. Aggreko: Investec places its target price (prev.: 1700p) under review and retains a hold recommendation. WH Ireland reduces target price from 2050p to 1700p downgrading from buy to outperform. Panmure Gordon reduces targ
Read moreLondon close: Markets lifted by corporate earnings, China outlook
24th Oct 2013 16:22
- FTSE 100 at levels not seen since May - China manufacturing PMI at seven-month high - Financials, miners and pharma stocks gain techMARK 2,642.27 +0.68% FTSE 100 6,713.18 +0.58% FTSE 250 15,526.93 +0.21% UK markets set a fresh five-month high on Thursday as investors celebrated an improved outlo
Read moreSector movers: Shire gives pharma sector a boost after Q3 beat
24th Oct 2013 15:31
Strong results from Shire injected some gains into the pharmaceuticals sector on Thursday after the company beat quarterly forecasts and hiked its guidance for the full year. The FTSE 100 specialty biopharmaceuticals stock was up an impressive 8.4% at 2,737p in afternoon trade following its results
Read moreAstrazeneca moves ahead with development of Selumetinib
22nd Oct 2013 07:55
Drugs giant AstraZeneca said Tuesday that it had initiated the third phase of its clinical programme for Selumetinib, a treatment which has been formulated for patients with a particular type of lung cancer. The group said the first patient with advanced (or metastatic) non-small cell lung cancer
Read moreFTSE 100 movers: Hargreaves Lansdown extends yesterday's gains
16th Oct 2013 15:14
Shares of Hargreaves Lansdown were leading gains on the Footsie and may have broken above technical resistance at the 1,044p mark after yesterday reporting record levels of assets under administration (AuA) in the fiscal first quarter. The financial services company reported AuA of £39.3bn in the
Read moreLondon pre-open: Strong start expected on FTSE as US hopes grow
15th Oct 2013 07:35
City sources predict the FTSE 100 will open around 35 points higher than yesterday's close of 6,507.65, tracking US stocks higher after they rallied to finish in positive territory on hopes that lawmakers are closing in on a deal to raise the debt ceiling and avert a default. The deal, which has ye
Read moreAstraZeneca acquires oncology-focused biotech firm
15th Oct 2013 07:01
AstraZeneca's biologics research and development arm, MedImmune, has acquired Spirogen, a privately-held biotech company focused on antibody-drug conjugate technology for use in oncology. The drugs giant said MedImmune has also entered into a collaboration agreement with ADC Therapeutics to jointly
Read moreAstraZeneca boosts oncology pipeline
7th Oct 2013 07:55
AstraZeneca announced Monday that MedImmune, its global biologics research and development arm, completed the acquisition of Amplimmune, a privately-held, US-based biologics company focused on developing novel therapeutics in cancer immunology. The deal was made to boost its oncology pipeline by o
Read moreLondon close: Stocks at one-month low on looming US shutdown
30th Sep 2013 16:36
Stocks were firmly lower on Monday as risk appetite was reduced in the face of a looming partial shutdown of the US government after a weekend of no progress in Washington. Political instability in Italy also dampened the mood today as well as disappointing economic data from China, with falls in t
Read moreAstrazeneca progresses with ovarian cancer drug
30th Sep 2013 14:43
AstraZeneca inched higher on Monday after announcing that the European Medicines Agency (EMA) has accepted its Marketing Authorisation Application (MAA) for olaparib, a drug used in the maintenance treatment of patients with a particular type of ovarian cancer. The group said olaparib has the pote
Read more